Solventum Corp (SOLV)

被低估

HealthcareMedical Instruments & SuppliesUnited States

基本面

价格

$86.85

市值

$15.24B

Yahoo Finance TradingView 新闻官网

第一部分 · 这家公司值多少

概览

Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies for original equipment manufacturers. The Dental Solutions segment provides dental and orthodontic products, including brackets, aligners, restorative cements, and bonding agents to span the life of the tooth, and products for preventative dental care, direct and indirect restoration, and orthodontic needs. The Health Information Systems segment offers healthcare systems with software solutions comprising computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms. The company sells its products and services through direct-to-consumer, distribution, key account management, inside sales, and e-commerce. Solventum Corporation was incorporated in 2023 and is headquartered in Eagan, Minnesota.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

资产负债表与流动性

营收

$8.31B

最近12个月（截至2026/6/30）

净利润

$1.43B

最近12个月（截至2026/6/30）

自由现金流

$-10M

股东权益合计

$5.05B

负债合计

$9.24B

流动比率

1.02

利息覆盖率

债务/EBITDA

1.98

每股收益

营收与净利润

自由现金流

收入构成

历史财务表

利润率变化

债务变化

债务负担有多重

增长一览表

增长 — 营业收入

公允价值估算

一般情形被低估

公允价值

$126.13

当前价格

$86.85

安全边际

+31.1%

公允价值区间

$81.98 - $170.27

所用估值方法之间的离散区间，并非经过统计校准的置信区间。

估算方法

分析师目标价:$93.92

现金流折现法（DCF）:$223.02

市盈率法（P/E）:$102.28

格雷厄姆成长公式:$133.17

盈利能力价值（EPV）:$106.28

合理市净率（P/B）:$128.34

股息折现模型（戈登模型）:数据不足，无法计算

P/FFO（运营资金）:$192.22

周期中段收益:数据不足，无法计算

市销率法（P/S）:$188.92

分析师共识:买入 (13B / 8H / 1S)

最近财报超预期:+31.15%

估值指标

市盈率（P/E）

10.76

ROE

30.8%

市净率（P/B）

3.13

P/FCF

毛利率

54.7%

ROIC

15.5%

盈利能力雷达图

价值创造（经济护城河）

ROIC

15.5%

WACC

6.3%

ROIC − WACC

+9.2 pp

ROIC 超过资本成本：公司正在为股东创造价值。

基本面分析标准

通过（15）

EPS shows upward trend
Price CAGR 15.07%
ROIC 15.5%
Gross Margin 54.7%
Debt/Equity ratio
Operating Margin 25.0%
Current Ratio
Debt/EBITDA
Return on Tangible Assets
ROE 29.0%
Analyst Consensus 59% Buy
Earnings Surprise avg 11.0%
Share Dilution 1.0%
Net Margin Trend 17.3% vs 4.5%
Piotroski F-Score 7/9

未通过（7）

EPS CAGR 4.51%
P/B Ratio 3.13
Positive Free Cash Flow
Low reliance on intangibles
Price below Graham Number
DCF valuation (Fairly valued)
Earnings Quality (OCF/NI) 0.15

不可用（6）

P/FCF NaN
Dividend Payout NaN%
CapEx intensity
Interest Coverage
Revenue Growth 5Y (Finnhub)
PEG Ratio (need PE > 0 and growth > 0)

Piotroski F-评分

7/9

财务状况强健

score

criteria

盈利质量

0.15

低质量：需深入审查会计处理

股权稀释

1.0%

股份数量稳定

机构持股

公司治理

管理团队

姓名	职位	年龄
Mr. Bryan C. Hanson	CEO & Director	58
Mr. Wayde D. McMillan	Executive VP & CFO	55
Ms. Amy Landucci	Chief Information & Digital Officer	50
Ms. Marcela A. Kirberger	Chief Corporate & Legal Affairs Officer & Corporate Secretary	58
Ms. Heather L. Knight	Chief Commercial Officer	53
Mr. Neil C. Zieselman	Senior VP, Controller & Chief Accounting Officer	49
Ms. Amy Wakeham	Senior Vice President of Investor Relations & External Finance Communications	-
Ms. Kate Dobbs	Chief Communications & Corporate Marketing Officer	-
Ms. Rachel H. Ellingson	Chief Strategy & Corporate Development Officer	55
Ms. Tammy L. Gomez	Chief Human Resources Officer	52

审计风险

董事会风险

薪酬风险

股东权利风险

第二部分 · 价格与买入时机

这一部分不判断公司是否值得拥有：它帮助你在基本面说服你之后，选择何时买入。包含：技术分析、潜力、历史回撤、Gamma 敞口。

文件

年度报告（10-K）
对公司业务、财务业绩和风险的年度概述。
提交日期：2026-02-27
查看文件
季度报告（10-Q）
最近三个月财务表现的最新情况。
提交日期：2026-08-05
查看文件
临时报告（8-K）
关于重大事件（如管理层变动或重要公告）的通知。
提交日期：2026-08-05
查看文件

via SEC EDGAR

损益历史

via SEC EDGAR

Latest News

Recent headlines for SOLV, sourced from Markets Gazette.

2/26/2026NEUTRAL
Solventum (SOLV) Q4 2025 Earnings Call Transcript
The transcript for Solventum Corporation's (SOLV) fourth-quarter 2025 earnings call has been made available, marking a routine event in the company's financial calendar. Solventum, a healthcare technology spin-off from 3M, is under investor scrutiny for its performance post-separation. While the release of the transcript is a standard step for transparency, the absence of the actual earnings content prevents an in-depth analysis. Investors are awaiting the detailed financial figures and future outlook to assess the business trajectory and potential implications for share value. Currently, the mere availability of the transcript, without the underlying data, provides no clear directional guidance for the market.

via Markets Gazette